Literature DB >> 30217274

Patient-reported outcomes and quality of life measures in atopic dermatitis.

Paras P Vakharia1, David Cella2, Jonathan I Silverberg3.   

Abstract

Atopic dermatitis (AD) is a complex and heterogeneous disorder with a profound symptom burden and harmful impact on multiple domains of quality of life (QOL). Many different patient-reported outcome (PRO) measures exist to assess clinical manifestations and QOL impairment in AD, but none comprehensively assess all aspects of the disease. This review addresses the PRO and QOL measures currently used in AD and their properties, strengths, weaknesses, and feasibility for assessing AD in randomized controlled trials and clinical practice. Currently, the patient-oriented eczema measure (POEM) has emerged as a preferred PRO for AD clinical manifestations, though no single instrument has developed as a preferred QOL measure. Validated PRO and QOL measures should be incorporated in all clinical trials of AD and in clinical practice where feasible.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30217274     DOI: 10.1016/j.clindermatol.2018.05.011

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  9 in total

1.  Validation of remote atopic dermatitis severity assessment with the Eczema Area and Severity Ondex in children using caregiver-provided photos and videos.

Authors:  Emily A Croce; Paul J Rathouz; Fabiana C P S Lopes; Maria Leszczynska; Lucia Z Diaz; Moise L Levy; Jennifer S Ruth; Pooja Varshney; Lynn Rew; Elizabeth C Matsui
Journal:  Pediatr Dermatol       Date:  2022-05-06       Impact factor: 1.997

2.  The role of the nurse in the care and management of patients with atopic dermatitis.

Authors:  Harmieke van Os-Medendorp; Elfie Deprez; Nele Maes; Sheila Ryan; Karina Jackson; Tonya Winders; Linda De Raeve; Christa De Cuyper; Steven Ersser
Journal:  BMC Nurs       Date:  2020-11-04

Review 3.  [Pruritus in atopic dermatitis-comparative evaluation of novel treatment approaches].

Authors:  Svenja Müller; Felix Witte; Sonja Ständer
Journal:  Dermatologie (Heidelb)       Date:  2022-06-10

Review 4.  Current Perspectives on the Systemic Management of Atopic Dermatitis.

Authors:  Danielle R Davari; Elizabeth L Nieman; Diana B McShane; Dean S Morrell
Journal:  J Asthma Allergy       Date:  2021-06-01

Review 5.  Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.

Authors:  Fatima Bawany; Carrie A Northcott; Lisa A Beck; Wilfred R Pigeon
Journal:  J Allergy Clin Immunol Pract       Date:  2020-12-13

6.  A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to-Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment.

Authors:  Richard D A Hudson; Mahreen Ameen; Susannah M C George; Catherine A Harwood; Richard B Weller; John T Lear; Rajesh Rout; Thishi Surendranathan; Milos Petrovic; Anthony P Bewley
Journal:  Clinicoecon Outcomes Res       Date:  2022-04-04

7.  Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients.

Authors:  Luca Mastorino; François Rosset; Federica Gelato; Michela Ortoncelli; Giovanni Cavaliere; Pietro Quaglino; Simone Ribero
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-17

8.  What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.

Authors:  J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu
Journal:  Br J Dermatol       Date:  2020-09-21       Impact factor: 9.302

9.  Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.

Authors:  J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-09-01       Impact factor: 6.166

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.